Document:

Exhibit 10.03

 

DIRECTOR FORM OPTION AWARD AGREEMENT

 

This Option Award Agreement
(this “Agreement”) is dated as of [___________], and is made by and between Eos Energy Enterprises, Inc., a
Delaware corporation (the “Company”), and the Participant whose name appears on the signature page to this Agreement
(“Director”). Capitalized terms used herein and not defined shall have the meaning ascribed to such terms in
the B. Riley Principal Merger Corp. II 2020 Incentive Plan, as amended from time to time.

 

Witnesseth:

 

Whereas,
the Board has adopted the Plan to motivate Eligible Persons of the Company or its Affiliates by providing them with an ownership
interest in the Company;

 

Whereas,
the Committee has approved the grant to Director of an Option to purchase the aggregate number of shares of Common Stock set forth
on the signature page to this Agreement, at the per share Exercise Price set forth on the signature page to this Agreement; and

 

Whereas,
Director and the Company desire to enter into an agreement to evidence and confirm the grant of such Option on the terms and conditions
set forth herein.

 

Now, therefore,
to evidence the Option so granted, and to set forth the terms and conditions governing such Option, the Company and Director hereby
agree as follows:

 

1. Grant.
The Company hereby evidences and confirms its grant to Director, effective as of the date hereof (the “Grant Date”),
of an Option to purchase the aggregate number of shares of Common Stock set forth on the signature page hereof (the “Shares”).
The Option shall have an Exercise Price per share (which is not less than the Fair Market Value as of the date hereof) set forth
on the signature page to this Agreement, and is not intended to be an Incentive Stock Option. 

 

2. Vesting
and Exercisability.

 

(a) Vesting.
Except as otherwise provided in this Agreement, subject to the continuous engagement of Director by the Company or any Affiliate
through the applicable vesting date, the Option shall fully vest and become exercisable on the earlier of (i) the first
anniversary of the Grant Date, and (ii) immediately prior to the date of the next annual shareholders meeting of the Company
following the Grant Date; provided, that, the Option shall vest in full upon the consummation of a Change in Control.

 

(b) Committee
Acceleration. The Committee may accelerate the vesting or exercisability of all or any portion of the Option, at any time
and from time to time. Notwithstanding the immediately preceding sentence, except as approved by the Committee, no Option shall
vest or become exercisable after the date on which Director receives a notice of termination of engagement from the Company or
tenders a notice of termination to the Company, as applicable.

 

3. Termination.

 

(a) Normal
Termination Date. Unless earlier terminated pursuant to Section 3(b), the Option shall terminate and be cancelled on the
fifth anniversary of the Grant Date (the “Normal Termination Date”).

 

     

     

    

 

(b) Early
Termination.

 

(i) For
Cause; Breach of Restrictive Covenants. In the event Director’s services to the Company and its Affiliates are terminated
by the Company for Cause, the Option (or portion thereof) then held by Director (whether or not then vested or exercisable) shall
be immediately forfeited and cancelled, in full, on the date of such termination of services. In addition, if, while Director is
bound by any restrictive covenants in favor of the Company and its Affiliates, Director breaches any such provision, the Option
(or portion thereof) then held by Director (whether or not then vested or exercisable) shall be immediately forfeited and cancelled,
in full, on the date of such breach.

 

(ii) For
Any Other Reason. In the event Director’s services to the Company and its Affiliates are terminated for any reason
other than a reason specified in Section 3(b)(i), the Option (or portion thereof) then held by Director that is then vested and
exercisable shall remain exercisable for a period of 12 months from the date of such termination, but in no event after the Normal
Termination Date.

 

(iii) Termination
of Unvested Option. The Option (or portion thereof) that is not vested and exercisable as of Director’s termination
of services shall be immediately forfeited and cancelled on the date of such termination of services.

 

4. Transferability.
Except as expressly permitted under Section 14(b) of the Plan, the Option may not be sold, transferred, pledged, assigned or otherwise
alienated or hypothecated, other than by will or by the laws of descent and distribution.

 

5. Exercise.

 

(a) Exercise
Generally. To the extent that the Option (or portion thereof) shall have become and remain vested and exercisable, and
subject to Section 3 and such administrative regulations as the Committee may have adopted, Director may exercise such Option in
accordance with the terms and conditions of Section 7(d) of the Plan.

 

(b) Limitations
on Exercise. Notwithstanding anything to the contrary contained in this Agreement, the Option may not be exercised in whole
or in part, and no notation shall be made in the books of the Company and/or certificates representing Shares shall be delivered,
unless (i) all requisite approvals and consents of any governmental authority of any kind having jurisdiction over the exercise
of the Option shall have been secured; (ii) the purchase of the Shares upon the exercise of the Option shall be exempt from
registration under applicable U.S. federal and state securities laws, and applicable non-U.S. securities laws, or the Shares shall
have been registered under such laws; and (iii) the aggregate Exercise Price shall have been paid and all applicable withholding
requirements shall have been satisfied.

 

6. Forfeiture;
Recovery of Compensation. By accepting, or being deemed to have accepted, the Option, Director expressly agrees to be bound
by the terms of any clawback or recoupment policy of the Company that applies to incentive compensation that includes the Option.
Nothing in the preceding sentence will be construed as limiting the general application of Section 7(a) of this Agreement.

 

7. General
Provisions.

 

(a) Plan
Provisions. The Option granted hereunder is being issued pursuant to and in accordance with the Plan (a copy of which has
been made available to Director) and, as such, is subject in all respects to the Plan, all of the terms of which are made a part
of and incorporated into this Agreement. In the event of any conflict between any term of this Agreement and the terms of the Plan,
the terms of the Plan shall control.

 

    2

     

    

 

(b) No
Rights as a Stockholder. Director shall have no voting or other rights as a stockholder of the Company with respect to
any Shares underlying the Option until the Option (or portion thereof) has been exercised in accordance with Section 7(d) of the
Plan and the Shares have been delivered to Director.

 

(c) Securities
Law Matters; Compliance with Rule 144.

 

(i) Securities
Law Matters. Director acknowledges that, until the Shares underlying this Option have been registered under the Securities
Act or such other state or foreign laws, as applicable, (A) the Shares underlying the Option have not been registered under
the Securities Act or any state or foreign securities or “blue sky” laws; (B) the Shares underlying the Option
must be held indefinitely and Director must continue to bear the economic risk of the investment in the Shares unless the Shares
are subsequently registered under the Securities Act and such state or foreign laws or an exemption from registration is available;
(C) when and if the Shares underlying the Option may be disposed of without registration in reliance upon Rule 144 of the
Securities Act (“Rule 144”), such disposition can generally be made only in limited amounts in accordance with
the provisions of such rule; and (D) a notation shall be made in the appropriate records of the Company indicating that
the Shares underlying the Option are subject to restrictions on transfer set forth in this Agreement and, if the Company should
in the future engage the services of a stock transfer agent, appropriate stop-transfer restrictions will be issued to such transfer
agent with respect to the Shares underlying the Option.

 

(ii) Compliance
with Rule 144. If any of the Shares underlying the Option are to be disposed of in accordance with Rule 144, Director shall
transmit to the Company an executed copy of Form 144 (if required by Rule 144) no later than the time such form is required to
be transmitted to the Securities and Exchange Commission for filing and such other documentation as the Company may reasonably
require to assure compliance with Rule 144 in connection with such disposition.

 

(d) Binding
Effect; Benefits; Assignability. This Agreement shall be binding upon and inure to the benefit of the parties to this Agreement
and their respective successors and assigns. Nothing in this Agreement, express or implied, is intended or shall be construed to
give any person other than the parties to this Agreement or their respective successors or assigns any legal or equitable right,
remedy or claim under or in respect of any agreement or any provision contained herein. Neither this Agreement nor any right, remedy,
obligation or liability arising hereunder or by reason hereof shall be assignable by the Company or Director without the prior
written consent of the other party.

 

(e) Amendment.
This Agreement may be amended, modified or supplemented only by a written instrument executed by Director and the Company; provided,
however, that, without Director’s consent, the Committee may amend (such amendment to have the minimum economic
effect necessary, as determined by the Committee in its sole discretion) this Agreement in such a manner as may be necessary or
appropriate to avoid having the Option become subject to the penalty provisions of Section 409A of the Code.

 

(f) Severability.
In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.

 

(g) Counterparts;
Section Headings. This Agreement may be executed in any number of counterpart, each of which shall be deemed to be an original,
and all of which together shall constitute one and the same instrument. The parties hereto agree to accept a signed facsimile or
portable document format copy of this Agreement as a fully binding original. Except as otherwise indicated, references herein to
any “Section” means a “Section” of this Agreement, and the section headings in this Agreement are for purposes
of reference only and shall not limit or define the meaning hereof.

 

--
Signature page follows --

    3

     

    

 

In Witness Whereof,
the Company and Director have executed this Option Award Agreement as of the date first above written.

 

	 	Eos Energy Enterprises, Inc.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Director
	 	 	 
	 	 
	 	[__]
	 	 	 
	 	Address:
	 	 	 
	 	 	 
	 	 	 

 

	Number of Shares of Common
    Stock subject to the Option:	[__]
	 	 
	Per Share Exercise Price:	$[____]

 

 

4Exhibit 10.1

 

 

From: Q Saeed Sterilumen, Inc. 8480 East Orchard Road, Suite 2400
Greenwood Village, Colorado 80111 To: Rhonda Wallen 640 College Ave, Boulder, CO 80302 Re: Offer of Employment Dear Rhonda: STERILUMEN
On behalf of Sterilumen, Inc. (the "Company") (NASDAQ: AUVI), I am pleased to extend you an offer of employment as the
company's Vice President of Product Marketing & Corporate Development ("VP") on the following terms (the "Employment
Offer".) 1. Position and Duties. The position of VP is offered on a full-time basis and your primary work location will be
Greenwood Village, Colorado. You will be expected to devote your full time and best efforts to the performance of your responsibilities,
as defined below, and you may not engage in any other business without the express written consent of the Company. Your job responsibilities
as VP are consistent with the normal job duties of a public company, NASDAQ listed Company in this position, including but not
limited to: • Engaging the leadership team and driving a culture of innovation you will report to directly to the Company's
CEO, Q Saeed. The Company may change your position, duties, and work location from time to time in its discretion necessary to
meet the demands of the business. • Be a leader on the team, manage and orchestrate marketers to ensure the success of all
product placement and adoption • Interview, hire and training any approved new team members and give regular feedback to
the team • Make data-driven decisions to hit company goals and create shareholder value • Develop and implement the
strategy for pricing, messaging, packaging, promotion and selling of our products

     

     

    

 

 

STERILUMEN • Collaborate with Sales to train and support
sales and customer support teams • Serve as an evangelist for our products through webinars, specific tradeshows and media,
thought leadership and blogging, social media and speaking • Keep the company digital presence (e.g. web sites, FB, Linkedin)
and assets up to date with market trends and competition • Collaborate with the senior leadership team and the Senior Business
Unit Leaders to think about corporate development opportunities in a progressive, systematic and routine fashion. Build relationships
with each business unit to keep an ongoing flow of ideas that is aligned with the business units' objectives • Serve as the
interface with partner companies and the point of coordination for all co investment and other activities with these companies
Partner with business leaders before, during and after the M&A processes, to ensure the deals make strategic sense, fit with
the forward-looking business plans, and are integrated smoothly and fully optimized Lead cross-functional teams in developing
acquisition business case analyses and executing and interfacing with finance, accounting, legal, tax, HR and other departments
of to ensure seamless deal execution Evaluate and execute other strategic initiatives such a patents, divestitures, licensing,
joint ventures and partnership activities Manage key deliverables including creating analyses, overseeing execution and identifying
next steps in process flow 2. Compensation and Employee Benefits. Your annual base salary for the period commencing December 8,
2020 will be $215,000.00 less applicable payroll deductions and withholdings, payable on the Company's regular payroll dates ("Starting
Salary"). You will be eligible for an annual variable "Bonus" at the discretion of the Board of Directors of up
to 25% of your Starting Salary. You will also be awarded certain "Stock Options" as to be presented approximately by
the end of 2020 and effective as of the effective date of your defined in, and subject to, the 2020 Employee Stock Option Plan.
Once your current company's health benefits expire, your COBRA costs will be covered at 50% of your costs incurred until Company
insurance is in effect. Please provide invoices for COBRA reimbursement with supporting cost documentation. During your employment,
you will also be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company,
including, but not limited to, profit sharing, life and disability insurance, health insurance, subject to plan terms and generally
applicable Company policies. The Company will reimburse you for your

     

     

    

 

 

STERILUMEN business travel and telephone in accordance with the
Company guidelines. In addition, you will be given a laptop computer that will be returned to the Company at the conclusion of
your employment. You will also be entitled to the paid holidays and other paid leave as set forth in the Company's policies. A
full description of these benefits is available upon request. The Company may change compensation and benefits from time to time
in its discretion. 3. "At-Will" Employment Relationship. Your employment with the Company will be "atwill."
This means that your employment is for no specific period of time and the Company may terminate your employment at any time and
for any reason whatsoever, with or without "cause" (defined below). The fact that your salary or other compensation
is stated in terms of years or months does not alter the at-will nature of the employment, and does not mean and should not be
interpreted to mean that you are guaranteed employment to the end of any period of time or for any period of time. Although your
job duties, title, compensation and benefits, as well as the Company's personnel policies and procedures, may change from time
to time, the "at-will" nature of your employment may only be changed expressly in a writing signed by you and the Company's
President or other authorized designee. (a) The term "cause" means (i) a material breach of any agreement between you
and the Company, including, without limitation, the company's governance, ethics, expenses and general conduct policies and practices,
and/or any non-competition agreement or confidentiality agreement (which will include any violation resulting from you working
for a competing company without the prior authorization and consent from the Company as contemplated by this Employment Offer);
(ii) intentional or negligent misconduct by you in the performance of your duties or obligations to the Company in any material
respect during your employment with the Company; (iii) a breach of any fiduciary duty which you owe to the Company in your capacity,
a manager of the Company, or under any agreement between you and the Company as an employee; (iv) the conviction, plea of guilty
or no contest or acceptance of deferred adjudication or unadjudicated probation by you during your employment with the Company
with respect to (A) a felony (other than a driving infraction) or (b) embezzlement, dishonesty, a crime involving moral turpitude,
or intentional and actual fraud; (v) the habitual use or abuse of alcohol, drugs or other substances, in each case that interferes
with your employment with the Company; (vi) 3

     

     

    

 

 

STERILUMEN material unexcused absences from work; (vii) your failure
to perform the job func~ ions , described above in paragraph 1, and failure to cure such deficiency within 7 business days after
being provided written notice of such fai lure. 4. Written Modifications Only. This letter forms the complete and exclusive statement
of the terms of your employment with the Company. It supersedes any other agreements or promises made to the Company, whether
oral or written, and nothing in this letter creates an implied or explicit contract for employment. Changes in your employment
terms, other than those changes expressly reserved to the Company's discretion in this letter, require a written modification
signed by an authorized representative of the Company. 5. Terms of Acceptance. If you wish to accept employment with the Company
under the terms described above, please sign and date this letter and return it to me by close of business December 7th. If you
accept our offer, we would like you to start on December 8, 2020. We are looking forward to the opportunity of working closely
with you in the near future. Sincerely, Keyoumars Saeed, CEO ACCEPTED AND AGREED: (Signature) Date: December 8, 2020 Date: December
8, 2020 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]